Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajooni Biotech's total inventories for the quarter that ended in Mar. 2026 was ₹395 Mil. Ajooni Biotech's average total inventories from the quarter that ended in Mar. 2025 to the quarter that ended in Mar. 2026 was ₹317 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ajooni Biotech's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹0.30.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ajooni Biotech's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ajooni Biotech (NSE:AJOONI) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Ajooni Biotech's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ajooni Biotech's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Ajooni Biotech Total Inventories Related Terms
Ajooni Biotech Total Inventories Historical Data
* Premium members only.
The historical data trend for Ajooni Biotech's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Ajooni Biotech (NSE:AJOONI) has a Total Inventories of ₹395 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ajooni Biotech and its competitors.
Is Ajooni Biotech's Total Inventories too high?
Ajooni Biotech's current Total Inventories is ₹395 Mil. Overall, Ajooni Biotech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ajooni Biotech's Total Inventories compare to KHC and GIS?
Ajooni Biotech's Total Inventories of ₹395 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Consumer Packaged Goods company?
A good Total Inventories depends on the Consumer Packaged Goods industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ajooni Biotech and its competitors. Ajooni Biotech's current Total Inventories is ₹395 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajooni Biotech stock overvalued right now?
Based on GuruFocus' analysis, Ajooni Biotech (NSE:AJOONI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.26, compared to a current price of ₹3.86 — trading 38.3% below its estimated fair value. The current Total Inventories is ₹395 Mil. Ajooni Biotech's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Ajooni Biotech (NSE:AJOONI), the current Total Inventories is ₹395 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajooni Biotech (NSE:AJOONI) Overvalued in 2026?
Based on GuruFocus' analysis, Ajooni Biotech stock appears to be undervalued.
The current stock price of ₹3.86 is trading 38.3% below its estimated GF Value™ of ₹6.26.
GuruFocus considers Ajooni Biotech to be Possible Value Trap.
Key valuation signals for NSE:AJOONI:
Total Inventories: ₹395 Mil
GF Value™: ₹6.26 vs. price of ₹3.86 (38.3% below fair value)
No single metric tells the full story. See the NSE:AJOONI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajooni Biotech Ltd is engaged in providing animal health care solutions dedicated to improving the productivity of Dairy farmers and sustainably increasing livestock yields. The company's products of cattle feed include Gold Pashu Aahar, Buff Plus, 3 Star, 4 Star, Calf Starter, & Transition Plus, and its feed supplements include Calvit, Batisa, Liv, Min, and other products. It derives majority portion of the revenue from the manufacturing of cattle feed. The company operates only in India.
64GF Score
Get the complete analysis for NSE:AJOONI
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJOONI has been successfully added to your 
